HUSSMAN STRATEGIC ADVISORS, INC. - CATALYST PHARMACEUTICALS INC ownership

CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 259 filers reported holding CATALYST PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.08 and the average weighting 0.1%.

Quarter-by-quarter ownership
HUSSMAN STRATEGIC ADVISORS, INC. ownership history of CATALYST PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$1,841,175
+47.3%
157,500
+69.4%
0.35%
+52.6%
Q2 2023$1,249,920
-18.9%
93,0000.0%0.23%
-5.0%
Q1 2023$1,541,940
+33.7%
93,000
+50.0%
0.24%
+28.7%
Q4 2022$1,153,200
+45.1%
62,0000.0%0.19%
+37.2%
Q3 2022$795,000
-12.7%
62,000
-52.3%
0.14%
-12.7%
Q2 2022$911,000
+61.5%
130,000
+91.2%
0.16%
+42.7%
Q1 2022$564,000
+22.6%
68,0000.0%0.11%
+8.9%
Q4 2021$460,000
-30.0%
68,000
-45.2%
0.10%
-30.3%
Q3 2021$657,000
-7.9%
124,0000.0%0.14%
-2.0%
Q2 2021$713,000124,0000.15%
Other shareholders
CATALYST PHARMACEUTICALS INC shareholders Q1 2023
NameSharesValueWeighting ↓
TANAKA CAPITAL MANAGEMENT INC 148,281$2,4587.14%
GABLES CAPITAL MANAGEMENT INC. 409,080$6,782,5464.74%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 10,355,099$171,687,5413.83%
JW Asset Management, LLC 563,392$9,341,0393.58%
Quantedge Capital Pte Ltd 324,700$5,383,5262.10%
Paradiem, LLC 236,628$3,923,2921.22%
SummerHaven Investment Management, LLC 100,592$1,667,8150.97%
Capital Impact Advisors, LLC 46,096$764,2720.94%
Yorktown Management & Research Co Inc 50,000$829,0000.89%
Seaport Global Advisors, LLC 15,598$258,6150.82%
View complete list of CATALYST PHARMACEUTICALS INC shareholders